UK approves world's first therapy with gene scissors

Developers of the Crispr method were awarded the Nobel Prize in 2020: a drug using the gene scissors has now been approved for the first time

17-Nov-2023 - (dpa) In the UK, a drug based on the gene-scissor technology Crispr has been approved for the first time worldwide. This was announced by the Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday. The drug, called "Casgevy", has been approved for the treatment of sickle cell ...

Merck Licenses Four Oncology Research and Development Programs from Vertex

Vertex receives upfront payment of $230 million plus royalties on future sales

12-Jan-2017 - Merck announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Inc. for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.“With this strategic deal we ...

Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

07-Nov-2012 - Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ...

Bend Research and Vertex Pharmaceutical enter new scientific collaboration

Bend Research to provide novel formulation development and manufacturing services for specific Vertex-led projects and clinical trials

11-Nov-2009 - Bend Research Inc. announced that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated. Through this new collaboration, Vertex will utilize Bend’s formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing ...

Vertex Pharmaceuticals: Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor

07-Dec-2005 - Vertex Pharmaceuticals Incorporated announced the initiation of a Phase II clinical trial for VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor for the treatment of HCV infection. The 28-day study will evaluate the safety, tolerability and pharmacodynamics of VX-950 when ...

New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury

06-Oct-2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV protease inhibitor being developed by Vertex Pharmaceuticals Incorporated, rapidly achieved substantial reductions in alanine aminotransferase (ALT) levels after 14 days ...

Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches

16-Apr-2004 - Berlin, Germany. New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals Incorporated were presented today at the Annual Meeting for the European Association for the Study of the Liver (EASL) in Berlin, Germany. ...